Celltrion's Zimfentra Achieves Record Prescription Volume in US Market

Celltrion's autoimmune disease treatment 'Zimfentra' is cruising in the US market, achieving its highest-ever quarterly prescription volume in the first quarter of this year. Celltrion has successfully implemented a marketing strategy targeting three key groups: physicians, insurance providers, and patients.

From the early stages of launch, the company intensified its sales activities by increasing touchpoints with major medical professionals and having its executives personally visit the US. Celltrion expanded its dedicated Zimfentra sales force to about 100 personnel, secured reimbursement coverage for over 90% of the US insurance market, and concurrently ran patient-focused marketing campaigns through various channels including TV, YouTube, and social media.

A Celltrion representative stated that the consistent breaking of prescription volume records each quarter proves the effectiveness of their customized sales activities aimed at key stakeholder groups.

Celltrion anticipates Zimfentra's growth trend to continue in the second half of the year. This outlook is attributed to a combination of factors, including increased awareness among medical professionals and patients, secured stable reimbursement coverage, and the ongoing record-breaking prescription volumes. The growth trajectory is expected to accelerate further, considering the prescription trends projected for the latter half of the year.